201 related articles for article (PubMed ID: 17127701)
1. Efficacy of percutaneous ethanol injection therapy (PEIT) is related to the number of parathyroid glands in haemodialysis patients with secondary hyperparathyroidism.
Koiwa F; Kakuta T; Tanaka R; Yumita S
Nephrol Dial Transplant; 2007 Feb; 22(2):522-8. PubMed ID: 17127701
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of percutaneous ethanol injection therapy for secondary hyperparathyroidism in patients on hemodialysis as evaluated by parathyroid hormone levels according to K/DOQI guidelines.
Tanaka M; Itoh K; Matsushita K; Matsushita K; Fukagawa M
Ther Apher Dial; 2005 Feb; 9(1):48-52. PubMed ID: 15828906
[TBL] [Abstract][Full Text] [Related]
3. Prognosis of parathyroid function after successful percutaneous ethanol injection therapy guided by color Doppler flow mapping in chronic dialysis patients.
Kakuta T; Fukagawa M; Fujisaki T; Hida M; Suzuki H; Sakai H; Kurokawa K; Saito A
Am J Kidney Dis; 1999 Jun; 33(6):1091-9. PubMed ID: 10352197
[TBL] [Abstract][Full Text] [Related]
4. Combination therapy of intravenous maxacalcitol and percutaneous ethanol injection therapy lowers serum parathyroid hormone level and calcium x phosphorus product in secondary hyperparathyroidism.
Tanaka M; Itoh K; Matsushita K; Matsushita K; Fukagawa M
Nephron Clin Pract; 2006; 102(1):c1-7. PubMed ID: 16166800
[TBL] [Abstract][Full Text] [Related]
5. Magnetic resonance imaging (MRI) and technetium-99m-methoxyisonitrile (MIBI) scintigraphy to evaluate the abnormal parathyroid gland and PEIT efficacy for secondary hyperparathyroidism.
Wada A; Sugihara M; Sugimura K; Kuroda H
Radiat Med; 1999; 17(4):275-82. PubMed ID: 10510900
[TBL] [Abstract][Full Text] [Related]
6. Long-term (3 years) prognosis of parathyroid function in chronic dialysis patients after percutaneous ethanol injection therapy guided by colour Doppler ultrasonography.
Tanaka R; Kakuta T; Fujisaki T; Tanaka S; Sakai H; Kurokawa K; Saito A
Nephrol Dial Transplant; 2003 Jun; 18 Suppl 3():iii58-61. PubMed ID: 12771303
[TBL] [Abstract][Full Text] [Related]
7. [Percutaneous ethanol injections in the treatment of secondary hyperparathyroidism].
Kuzdak K; Rybińska A; Białas M
Endokrynol Pol; 2005; 56(6):891-6. PubMed ID: 16821207
[TBL] [Abstract][Full Text] [Related]
8. Percutaneous ethanol (PEIT) and calcitrol (PCIT) injection therapy are ineffective in treating severe secondary hyperparathyroidism.
de Barros Gueiros JE; Chammas MC; Gerhard R; da Silva Dias Boilesen CF; de Oliveira IR; Moysés RM; Jorgetti V
Nephrol Dial Transplant; 2004 Mar; 19(3):657-63. PubMed ID: 14767023
[TBL] [Abstract][Full Text] [Related]
9. Clinical experience with percutaneous ethanol injection therapy in hemodialysis patients with renal hyperparathyroidism.
Nakamura M; Fuchinoue S; Teraoka S
Am J Kidney Dis; 2003 Oct; 42(4):739-45. PubMed ID: 14520624
[TBL] [Abstract][Full Text] [Related]
10. Long-term prognosis of parathyroid function after successful percutaneous ethanol injection therapy (PEIT) guided by color Doppler flow mapping in chronic dialysis patients.
Kakuta T; Kunimatsu K; Tadaki F; Fujisaki T; Noguchi M; Abe Y; Sakai H; Kurokawa K; Saito A
Biomed Pharmacother; 2000 Jun; 54 Suppl 1():60s-65s. PubMed ID: 10914993
[TBL] [Abstract][Full Text] [Related]
11. [A case of secondary hyperparathyroidism with an ectopic intrathyroid gland successfully diagnosed and controlled by percutaneous ethanol injection therapy (PEIT)].
Tanaka M; Itoh K; Matsushita K; Ogawa A; Hirayama H; Tsunoda N; Yoshizumi K; Naruse M; Nonoguchi H; Tomita K
Nihon Jinzo Gakkai Shi; 2002 May; 44(4):409-13. PubMed ID: 12073627
[TBL] [Abstract][Full Text] [Related]
12. Percutaneous ethanol injection therapy: a surgery-sparing treatment for primary hyperparathyroidism.
Stratigis S; Stylianou K; Mamalaki E; Perakis K; Vardaki E; Tzenakis N; Katsipi I; Papavasiliou S; Yarmenitis S; Kyriazis J; Daphnis E
Clin Endocrinol (Oxf); 2008 Oct; 69(4):542-8. PubMed ID: 18331604
[TBL] [Abstract][Full Text] [Related]
13. Number of enlarged parathyroid glands might be a predictor of cinacalcet response in advanced secondary hyperparathyroidism.
Yamamoto M; Ogata H; Mizobuchi M; Yoshida N; Kumata-Maeta C; Koiwa F; Shishido K; Kinugasa E
Clin Exp Nephrol; 2012 Apr; 16(2):292-9. PubMed ID: 22011886
[TBL] [Abstract][Full Text] [Related]
14. Percutaneous ethanol injection therapy in post-transplant patients with secondary hyperparathyroidism.
Douthat WG; Orozco SE; Maino P; Cardozo G; de Arteaga J; de la Fuente J; Chiurchiu CR; Massari PU
Transpl Int; 2007 Dec; 20(12):1031-5. PubMed ID: 17883371
[TBL] [Abstract][Full Text] [Related]
15. Relationship between the dimension of parathyroid glands estimated by ultrasonography and the hyperplastic pattern in patients with renal hyperparathyroidism.
Matsuoka S; Tominaga Y; Sato T; Uno N; Hiramitu T; Goto N; Nagasaka T; Uchida K
Ther Apher Dial; 2008 Oct; 12(5):391-5. PubMed ID: 18937723
[TBL] [Abstract][Full Text] [Related]
16. Early intervention with intravenous or pulse oral vitamin D therapy is more effective in the treatment of secondary hyperparathyroidism.
Yamada S; Taniguchi M; Tokumoto M; Tsuruya K; Hirakata H; Iida M
Ther Apher Dial; 2010 Aug; 14(4):424-31. PubMed ID: 20649764
[TBL] [Abstract][Full Text] [Related]
17. Role of the parathyroid gland vascularization index in predicting percutaneous ethanol injection efficacy in refractory uremic hyperparathyroidism.
Chen HH; Lu KC; Lin CJ; Wu CJ
Nephron Clin Pract; 2011; 117(2):c120-6. PubMed ID: 20693813
[TBL] [Abstract][Full Text] [Related]
18. Time course of change in calcium x phosphorus product after percutaneous ethanol injection therapy.
Koiwa F; Hasegawa T; Kojima I; Ideura T
Nephrol Dial Transplant; 2003 Jun; 18 Suppl 3():iii53-7. PubMed ID: 12771302
[TBL] [Abstract][Full Text] [Related]
19. Parathyroid interventions for secondary hyperparathyroidism in hemodialyzed patients.
Onoda N; Kashiwagi T; Nakamura T; Niitsu Y; Omata M; Kurihara S
Ther Apher Dial; 2005 Aug; 9 Suppl 1():S11-5. PubMed ID: 16109135
[TBL] [Abstract][Full Text] [Related]
20. Clinical features and hyperplastic patterns of parathyroid glands in hemodialysis patients with advanced secondary hyperparathyroidism refractory to maxacalcitol treatment and required parathyroidectomy.
Tominaga Y; Matsuoka S; Sato T; Uno N; Goto N; Katayama A; Haba T;
Ther Apher Dial; 2007 Aug; 11(4):266-73. PubMed ID: 17661832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
